Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Bayer AG

6 abstracts

Abstract
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.
Org: The University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre, NCT Heidelberg, Charité Universitätsmedizin Berlin, Prisma Health Cancer Institute,
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).
Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017-2023: An administrative claims database study.
Org: Bayer HealthCare Pharmaceuticals Inc., Bayer AG, Bayer Ltd, Bayer Consumer Care AG, Duke Cancer Institute Center for Prostate and Urologic Cancers,
Abstract
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.
Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Humanitas University, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki University Hospital Comprehensive Cancer Center, Semmelweis University,
Abstract
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.
Org: Bayer AG, Charité - Universitätsmedizin Berlin, Berlin, Germany, University of Munich, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Germany,
Abstract
BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
Org: Bayer AG, Staburo GmbH, StatFinn Oy,